Sort
82,697 grants matching “vaccine development”
Influenza Vaccine Development
$1,402,202Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
RP2: Broad Spectrum SiRNA Marburg
$1,401,721Ian Maclachlan · University Of Texas Med Br Galveston · U19 · FY2014 · AI
Molecular Analysis of Tuberculosis Immunity
$1,401,616William Robert Jacobs · Albert Einstein College Of Medicine · P01 · FY2008 · AI
Dengue Epitope Vaccine,Tetravalent & MHCII-Targeted
$1,401,389J. Thomas Thomas August · Johns Hopkins University · U19 · FY2007 · AI
Multiscale Analysis of Immune Responses
$1,401,360Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
HIV/SIV Replication In Vivo
$1,401,317Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
HIV/SIV Replication In Vivo
$1,401,317Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Antigen Processing And Presentation In The Intestine
$1,401,182Brian Kelsall · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Development Of New Approaches To Vaccines Against TBEV and West Nile Virus
$1,401,155Alexander Pletnev · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY
$1,400,997Aravinda M De Silva · Univ Of North Carolina Chapel Hill · R01 · FY2016 · AI
The connection of innate and adaptive anti-cancer immunity
$1,400,831John Greiner · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Developing/Testing a Multi-level Interventions (SHIELD & IWC)
$1,400,721Sujha Subramanian · Research Triangle Institute · UH3 · FY2021 · HD
REAGENT RESOURCE SUPPORT FOR AIDS VACCINE DEVELOPMENT
$1,400,554Quality Biological, Inc. · N01 · FY2000 · AI
HIV-1 and host interactions at molecular level
$1,400,080Maureen Goodenow · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
RFA-IP-22-004, Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
$1,400,000Karen J Wernli · Kaiser Foundation Health Plan Of Washington · U01 · FY2023 · IP
HIVR4P 2023, the 5th HIV Research for Prevention Conference, Lima, Peru, and virtually, 22-26 October 2023
$1,400,000Chris Beyrer · Ias · R13 · FY2023 · AI
HIV Research for Prevention 2018: Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P)
$1,400,000Georgia D Tomaras · Duke University · R13 · FY2018 · AI
RFA-IP-22-004, Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines
$1,400,000Emily Toth Martin · University Of Michigan At Ann Arbor · U01 · FY2023 · IP
DNA Based Generation of Avian Influenza virus Vaccines
$1,400,000Sanofi Pasteur, Inc. · UC1 · FY2000 · AI
Small Molecular Inactivators of HIV
$1,400,000Daniel H Appella · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
HIV Research for Prevention Conference, HIVR4P 2020
$1,400,000Chris Beyrer · Ias · R13 · FY2020 · AI
Preclinical Development of a Recombinant Dengue Vaccine
$1,399,858Hawaii Biotech, Inc. · U01 · FY2004 · AI
Natural History of HPV Infection to Neoplasia
$1,399,693Anna-Barbara None Moscicki · University Of California, San Francisco · R37 · FY2013 · CA
Molecular Analysis of Tuberculosis Immunity
$1,399,546William Robert Jacobs · Albert Einstein College Of Medicine · P01 · FY2006 · AI
Cytokines in AIDS and Cancer Immunotherapy
$1,399,536George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA